The accelerated data readout is a positive catalyst; traders should position ahead of mid-May 2026 for potential volatility. A positive readout could validate the pan-RAS mechanism and significantly re-rate the stock, given ERAS-0015's potential in a high-unmet-need oncology space.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 21 $22.41entry
- T+1 · 7mo ago −3.39%α −4.41% · $21.65
- T+5 · 7mo ago −55.82%α −56.91% · $9.90
- T+20 · 6mo ago −54.17%α −59.09% · $10.27
- T+60 · 4mo ago −15.13%α −22.03% · $19.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca, Inc. updated guidance, narrowing the expected timing for the Phase 1 monotherapy data readout of its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 trials to no later than mid-May 2026, an acceleration from prior 'first half of 2026' guidance. This clinical milestone is critical for validating the drug's efficacy in RAS-mutant solid tumors.
Key Facts
- Erasca narrowed the anticipated Phase 1 monotherapy data readout for ERAS-0015 to no later than mid-May 2026, up from prior guidance of first half of 2026.
- Data will come from two trials: AURORAS-1 (Erasca's trial in RAS-mutant solid tumors) and JYP0015M101 (conducted by licensor Joyo in China).
- ERAS-0015 is a pan-RAS molecular glue, a novel mechanism targeting a key oncogenic pathway with high therapeutic potential.
Financial Impact
No direct financial impact disclosed. The event is a clinical milestone that could significantly influence future valuation and partnership potential.
Risk Factors
- Clinical data may not meet efficacy or safety expectations, leading to a sharp decline.
- The accelerated timeline increases near-term event risk and stock volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-165297 |
| Document: 0001193125-26-165297-index-headers.html | 0001193125-26-165297 |
| Document: 0001193125-26-165297-index.html | 0001193125-26-165297 |
| Document: 0001193125-26-165297.txt | 0001193125-26-165297 |
Track record
26 reports on ERAS
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers